Last reviewed · How we verify
Pertussis containing vaccine
A pertussis-containing vaccine stimulates the immune system to produce antibodies and cellular immunity against Bordetella pertussis, the bacterium that causes whooping cough.
A pertussis-containing vaccine stimulates the immune system to produce antibodies and cellular immunity against Bordetella pertussis, the bacterium that causes whooping cough. Used for Prevention of pertussis (whooping cough) in infants, children, and adults, Prevention of diphtheria and tetanus (when in combination formulations).
At a glance
| Generic name | Pertussis containing vaccine |
|---|---|
| Also known as | Boostrix, Repevax |
| Sponsor | St George's, University of London |
| Drug class | Bacterial vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated pertussis toxin and other bacterial antigens that trigger both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly eliminate B. pertussis upon natural exposure, preventing infection or reducing disease severity. Pertussis vaccines are typically combined with diphtheria and tetanus toxoids (DPT or Tdap formulations).
Approved indications
- Prevention of pertussis (whooping cough) in infants, children, and adults
- Prevention of diphtheria and tetanus (when in combination formulations)
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- Maternal Determinants of Infant Immunity to Pertussis (PHASE4)
- Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Adults (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- 10-year Follow-up After a Single Dose Acellular Pertussis Vaccination (PHASE4)
- Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (PHASE2)
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
- Optimising Protection for Pregnant Women and Infants With Maternal Vaccination
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pertussis containing vaccine CI brief — competitive landscape report
- Pertussis containing vaccine updates RSS · CI watch RSS
- St George's, University of London portfolio CI